Japan Tobacco Inc.

Other

Daido Metal Company Ltd.

Agouron Pharmaceuticals, Inc.

Tobishi Yakuhin Kogyo Kabushiki Kaisha

Leo-pharma A/s

Nec Corporation

Kabushiki Kaisha Kobe Seiko Sho

Takashi Inaba

Yasuki Yamada

Takayuki Shibayama

Koichi Yamamoto

Tsutomu Inoue

Naohisa Kawakami

Kenji Sakai

Satoru Kurimoto

Masatoshi Hagiwara

Yasuo Ido

Hiroyoshi Hidaka

Masahiro Tanaka

Frank Kayser

Brian M Fox

Soren Ebdrup

Kexue Li

Anders Klarskov Petersen

Michael E Deason

Hiroshi Yamamoto

Akira Endo

Steven Wade Andrews

Hiroyuki Abe

Masaaki Sakamoto

Julia Haas

Masayuki Takada

Isao Umezawa

Takuya Matsuo

Ellen Ruth Laird

Dustin L McMinn

Xiaolin Hao

Marc Labelle

Takahiro Yamasaki

Toshiki Ueda

Akihiro Tsuruno

Masanori Ikeda

Simon Mark Jackson

Steven Marc Rubenstein

Masafumi Inoue

Tsukimitsu Higuchi

Yasuhiro Nishioka

Eiji Kato

Fumihiro Koshigoe

Jian Zhang

Tomohiro Nishimura

Takahisa Motomura

Yoshinori Kato

Hideyuki Kidokoro

Koichi Suzawa

Yoshikazu Hori

Toshio Egami

Masaki Tanigawa

Masayuki Yuasa

Osamu Sakuma

Tadashi Morita

Tomohiko Ishikawa

Tadashi Toshioka

Tetsudo Kaya

Shoichi Sagawa

Tsubasa Takeichi

Hiroyuki Iwamura

Kenji Naitoh

Atsuhito Yoshida

Takashi Watanabe

Kiyosei Iio

Akinobu Higashi

Hiromu Takiguchi

Kim Lebek Jensen

Per Vedsoe

Jan Bornholdt

James Shanley

Noboru Furukawa

Makoto Shiozaki

Yukio Naruse

Eiki Usui

Hirotsugu Ito

Kazuyuki Sugimoto

Takao Ito

Koji Kitagawa

Kenji Tokuda

Akira Suma

Takuya Matsui

Shohei Sakata

Hiroshi Maegawa

Atsunori Kashiwagi

Kenji Naito

Shinpei Kidokoro

Horoyoshi Hidaka

Susumu Tuzi

Nicole M Littmann

Yukimaro Tsukamoto

Katsutaka Yasue

Atushi Sakai

Andrew M Fryer

Yasuyuki Kajimoto

Takafumi Matsuo

Yuichi Shinozaki

Hiroto Imai

Tamotsu Negoro

Nobuya Ogawa

Masahiro Suzuki

The present invention provides processes for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives, which are useful as a Janus kinase (JAK) inhibitor, intermediates thereof, and processes for preparing the intermediates. The present invention provides processes for preparing 3-[(3S,4R)-3-methyl-6-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)-1,6-diazaspiro[3.4]octan-1-yl]-3-oxopropanenitrile using salts of (3S,4R)-1-benzyl-3-methyl-1,6-diazaspiro[3.4]octane with organic acids.

Process for preparing 7H-pyrrolo[2,3-d]pyrimidine derivatives and synthetic intermediates thereof

A production method of a compound represented by the formula [I]: or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

Production method for pyrazole-amide compound

The present invention provides a compound having aggrecanase inhibitory activity and MMP-13 inhibitory activity, and useful as a therapeutic agent for osteoarthritis, rheumatoid arthritis and the like, more specifically, a cyclopropane compound of formula (1): wherein Ris &#x2014;(CH)&#x2014;X&#x2014;(CH)-Aetc., wherein m and n are the same or different and each is 0 to 6, X is a single bond, etc. and Ais a substituted Chydrocarbon ring group, etc.; Rand Rare the same or different and each is a hydrogen atom, &#x2014;(CH)&#x2014;X&#x2014;(CH)-A, etc., wherein p and q are the same or different and each is 0 to 6, Xis a single bond, etc. and Ais an optionally substituted Chydrocarbon ring group, etc.; Ris &#x2014;COR, etc., wherein Ris a hydrogen atom, etc.; and Rand Rare the same or different and each is a hydrogen atom, &#x2014;(CH)&#x2014;X&#x2014;(CH)&#x2014;R, etc., wherein m12 and m12 are the same or different and each is 0 to 6, Xis a single bond, etc. and Ris a hydrogen atom, etc.; or a prodrug thereof or a pharmaceutically acceptable salt thereof.

Cyclopropane compounds and pharmaceutical use thereof

Compounds, pharmaceutical compositions and methods that are useful in the treatment or prevention of metabolic and cell proliferative diseases or conditions are provided herein. In particular, the invention provides compounds which modulate the activity of proteins involved in lipid metabolism and cell proliferation.

[object Object]

Fused bicyclic nitrogen-containing heterocycles

The present invention relates to an azole compound represented by the formula [I] wherein W is S or O; R is &#x2014;COOR, &#x2014;X-A-COOR(Ris H, alkyl) or tetrazolyl; R, R, Rand Rare H and the like; A is &#x2014;(CH)&#x2014;X&#x2014; (X is &#x2014;N(R)&#x2014;, &#x2014;C(R)(R)&#x2014;, &#x2014;CO&#x2014; or &#x2014;CO&#x2014;N(R)&#x2014;); B is aryl or aromatic heterocyclic group; Ris H and the like; Ris &#x2014;(Y)-(A)-Z (Y is &#x2014;O&#x2014;, &#x2014;S(O)&#x2014;, &#x2014;N(R)&#x2014;, &#x2014;N(R)&#x2014;CO&#x2014;, &#x2014;N(R)&#x2014;SO&#x2014;, &#x2014;SO&#x2014;N(R)&#x2014; and the like, Ais alkylene, and Z is cycloalkyl, aryl, aromatic heterocyclic group, indanyl, piperazinyl, a prodrug thereof or a pharmaceutically acceptable salt thereof. The compound [I] of the present invention has a protein tyrosine phosphatase 1B inhibitory activity, and is useful as a therapeutic agent for diabetes, a therapeutic drug for diabetic complications or a therapeutic drug for hyperlipidemia.

Azole compound and medicinal use thereof

A copper-based sliding material comprising sintered copper or sintered copper alloy, and 0.1 to 5 vol. % hard substance particles harder in hardness than said copper or copper alloy, said hard substance particles being substantially evenly dispersed so that, when at least one, randomly selected surface portion or sectional portion of said sintered copper or sintered copper alloy is partitioned into squares each having a side of 20 &#x3bc;m, at least one particle exists in each of squares not less than 80% of the whole squares. The copper-based sliding material has good anti-seizure property and superior resistance to fatigue without containing any lead.

Sliding material made of copper alloy, method of producing same, sliding bearing material, and method of producing same

2-oxoquinoline compounds and pharmaceutical uses thereof

A portable fuel cell stack is provided in which the number of components is reduced by reducing the number of flow field plates, cell performance is improved by reducing the number of contact portions to thereby lower internal resistance, and fuel is supplied from the center of an end plate directly to a fuel distribution manifold. The portable fuel cell stack includes two end plates, a plurality of unit cells positioned between the two end plates, a fuel distribution manifold positioned in the center of the unit cell for fuel supply thereto, a tie bolt passed through the centers of the fuel manifold and the unit cell for integration of these members, and fixing nuts threaded to both ends of the tie bolt for integrally clamping the plurality of unit cells together between the end plates via an O-ring, etc. The unit cell includes a polymer electrolyte membrane, an oxygen electrode and a fuel electrode installed on both sides of the polymer electrolyte membrane, a flow field plate adjacent to the oxygen electrode side, and a separator plate on the outside of the flow field plate adjacent in contact therewith and another separator plate on the outside of the fuel electrode side in contact therewith. One of the fixing nuts has a fuel supply port connecting to the fuel distribution manifold.

Portable fuel cell stack

A copper-based sliding material produced by sintering, comprising at least two phases of copper and/or copper alloys which phases have hardness levels different form each other, and hard particles with an average particle size of 0.1 to 10 &mgr;m which are dispersed in at least one phase with the exception of a softest phase in an amount of 0.1 to 10 vol. % of the whole copper-based sliding material, said sliding material satisfying (H2/H1)&gE;1.2 in which H1 is the Vickers hardness of the softest phase and in which H2 is the Vickers hardness of a phase hardest in hardness including said hard particles.

Copper-based sliding material, method of manufacturing the same, and sliding bearing

Methods for producing amide derivative

2-oxoquinoline compounds and medicinal uses thereof

4-(2-amino-1-hydroxyethyl)oxazoline derivative and method for producing same

A copper alloy sliding material which can bring about superior resistance to fatigue as well as good anti-seizure property without containing any Pb. The copper alloy sliding material is made to have the structure in which both of the hard copper alloy phase and the soft copper alloy phase coexist in a mixture state. On the surface of the sliding material, the soft copper alloy phase comes to have a shape more concave than that of the hard copper alloy phase when receiving a load or when being in a sliding wear relation, in which concave portions is retained lubricant with the result that the anti-seizure property is enhanced. Further, since the soft phase and the hard phase are made of the same copper alloy, the wettability thereof becomes good, and Ni and etc. contained in the hard copper alloy phase are diffused into the soft copper alloy phase, so that the hardness of the boundary portion defined between the phases come to be gradually varied. Thus, because of the unclear boundary, the load received in the hard phase comes to be spread in a wide range without being concentrated at the boundary, so that the fatigue strength is enhanced.

Sliding material made of copper alloy, method of producing same, and sliding bearing

Growing community of inventors

Takatsuki, Japan

Takashi Inaba